Literature DB >> 22392337

(1)H, (13)C, and (15)N chemical shifts assignments for human endothelial monocyte-activating polypeptide EMAP II.

Dmytro Lozhko1, Jan Stanek, Krzysztof Kazimierczuk, Anna Zawadzka-Kazimierczuk, Wiktor Kozminski, Igor Zhukov, Alexander Kornelyuk.   

Abstract

Endothelial and monocyte-activating polypeptide II (EMAP II) is a cytokine that plays an important role in inflammation, apoptosis and angiogenesis processes in tumour tissues. Structurally, the EMAP II is a 169 amino acid residues long C-terminal domain (residues 147-312) of auxiliary tRNA binding protein p43. In spite of existence in pdb databank of two X-ray structures there are some important aspects of EMAP II cytokine function which are still not fully understood in detail. To obtain information about 3D structure and backbone dynamic processes in solution we perform structure evaluation of human EMAP II cytokine by NMR spectroscopy. The standard approach to sequence-specific backbone assignment using 3D NMR data sets was not successful in our studies and was supplemented by recently developed 4D NMR experiments with random sampling of evolution time space. Here we report the backbone and side chain (1)H, (13)C, and (15)N chemical shifts in solution for recombinant EMAP II cytokine together with secondary structure provided by TALOS + software.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392337     DOI: 10.1007/s12104-012-9369-y

Source DB:  PubMed          Journal:  Biomol NMR Assign        ISSN: 1874-270X            Impact factor:   0.746


  2 in total

1.  MiR-429 Regulated by Endothelial Monocyte Activating Polypeptide-II (EMAP-II) Influences Blood-Tumor Barrier Permeability by Inhibiting the Expressions of ZO-1, Occludin and Claudin-5.

Authors:  Liangyu Chen; Yixue Xue; Jian Zheng; Xiaobai Liu; Jing Liu; Jiajia Chen; Zhen Li; Zhuo Xi; Hao Teng; Ping Wang; Libo Liu; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2018-02-07       Impact factor: 5.639

2.  EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma.

Authors:  Manal Mohamed Saber
Journal:  J Immunol Res       Date:  2022-09-12       Impact factor: 4.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.